Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/680,935
				Filing Date	October 2, 2003
				First Named Inventor	David Bar-Or
				Art Unit	1644
				Examiner Name	Amy E. Juedes
Sheet	1	of	1	Attorney Docket Number	6134-81

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.[1]	Document Number Number-kind Code [2] *(if known)*	Publication Date MM-DD-YYYY	Name of Patentee of Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]; Number[4]; Kind Code[5] *(if known)*	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]

OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)		
Examiner Initials*	Cite No.[1]	
	1	Lim et al. "Characterization of transthyretin variants in familial transthyretin amyloidosis by mass spectrometric peptide mapping and DNA sequence analysis", 2002, Anal. Chem. 74, pages 741-751
	2	Kishikawa, "Enhanced amyloidogenicity of sulfonated transthyretin in vitro, a hypothetical etiology of senile amyloidosis" 1999, Amyloid, Vol. 6, No. 3, pages 183-186
	3	Haque et al. "Cysteinylation of MHC class II ligands: peptide endocytosis and reduction within APC influences T cell recognition.", The Journal of Immunology, 2001, 166(7), 4543-4551
	4	Guo W et al., 2002 "Tyrosine phosphorylation of the NR2B subunit of the NMDA receptor in the spinal cord during the development and maintenance of inflammatory hyperalgesia" J. Neurosci. Jul 15; 22(14):6208-17
	5	Han J et al., "A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells" 1994 Science 265, 808-811

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference is considered, whether or not citation is in conformance and not considered. Include copy of this form with next communication to applicant.